How should hyperosmolar hyperglycemic state (HHS) or diabetic ketoacidosis (DKA) be managed in a patient on maintenance dialysis for chronic kidney disease (CKD) who also has a prior cerebrovascular accident (CVA), coronary artery disease (CAD) status post percutaneous coronary intervention (PTCA), and hypertension (HTN)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of DKA/HHS in Dialysis Patients with Multiple Comorbidities

In patients on maintenance dialysis with CKD, CVA, CAD s/p PTCA, and HTN presenting with DKA or HHS, you must drastically modify standard protocols: use minimal fluid resuscitation (avoid standard 1-1.5L boluses), reduce insulin infusion rates by approximately 50%, avoid routine potassium supplementation initially, and strongly consider emergency dialysis for severe acidosis or volume management. 1

Critical Modifications Required

Fluid Management - The Most Dangerous Pitfall

Standard DKA/HHS protocols call for aggressive fluid resuscitation (15-20 mL/kg/h or 1-1.5L in the first hour) 2, 3, but this approach is catastrophic in dialysis patients. Your patient has:

  • No renal clearance capacity - cannot excrete excess fluid
  • CAD s/p PTCA - vulnerable to volume overload and pulmonary edema
  • Prior CVA - at risk for cerebral edema with rapid osmolality shifts

Specific fluid approach:

  • Start with 250-500 mL isotonic saline over 1 hour (not the standard 1-1.5L) 1
  • Monitor closely for signs of volume overload: jugular venous distension, pulmonary crackles, oxygen desaturation
  • Target osmolality reduction <3 mOsm/kg/h (even more conservative than standard <3 mOsm/kg/h) 4
  • Consider emergency dialysis early rather than aggressive IV fluids for volume management 5, 6

The 2022 AACE guideline explicitly warns: "Caution is recommended in persons with advanced renal failure because standard IV fluid and insulin replacement may result in increased volume overload and hypoglycemia." 1

Insulin Dosing - Reduce by Half

Standard protocols use 0.1 units/kg/h continuous IV insulin 2, 7, 3, but dialysis patients have:

  • Markedly reduced insulin clearance (kidney normally clears 30-80% of insulin) 8
  • Decreased gluconeogenesis
  • Impaired insulin degradation due to uremia 8, 6

Specific insulin approach:

  • Start at 0.05 units/kg/h (half the standard rate) 1, 5
  • Target glucose decline of 50-75 mg/dL/h (same target, but achieved with less insulin) 2
  • Avoid initial bolus in dialysis patients 5
  • Monitor glucose every 1-2 hours initially
  • When glucose reaches 250 mg/dL (DKA) or 300 mg/dL (HHS), reduce insulin further to 0.025-0.05 units/kg/h 2

Potassium Management - The Opposite Problem

Standard protocols emphasize aggressive potassium replacement (20-40 mEq/L in fluids once K+ <5.3) 2, 3, but dialysis patients are at extreme risk for hyperkalemia, not hypokalemia.

Specific potassium approach:

  • Check potassium immediately - do not start insulin if K+ >5.5 mEq/L 6
  • Withhold potassium supplementation initially in dialysis patients 5, 6
  • If K+ <3.3 mEq/L, hold insulin and give potassium cautiously (10-20 mEq/h maximum)
  • Monitor K+ every 2 hours - insulin drives potassium intracellularly, but reduced renal clearance creates unpredictable dynamics
  • Have emergency dialysis immediately available for severe hyperkalemia (K+ >6.5 or ECG changes)

The 2022 guideline notes: "Severe hypokalemia (K ≤2.5 mEq/L) and severe hypoglycemia (BG <40 mg/dL) have been associated with increased mortality." 1 However, in dialysis patients, hyperkalemia is the more immediate threat.

Bicarbonate Therapy - Consider More Liberally

Standard guidelines recommend bicarbonate only for pH <6.9 2, 7, 2, but dialysis patients:

  • Cannot excrete acid load renally
  • May have baseline metabolic acidosis from uremia
  • Are at higher risk for severe, refractory acidosis 6

Specific bicarbonate approach:

  • Consider bicarbonate therapy at pH <7.0 (higher threshold than standard <6.9) in dialysis patients 6
  • Give 50-100 mmol sodium bicarbonate in 200-400 mL sterile water over 1-2 hours
  • Alternative: Emergency dialysis with bicarbonate-based dialysate is often more effective and safer than IV bicarbonate 5, 6

Emergency Dialysis Indications

Strongly consider emergency hemodialysis for: 5, 6

  • Severe metabolic acidosis (pH <7.0) not responding to conservative measures
  • Hyperkalemia (K+ >6.0 mEq/L or rising despite insulin)
  • Volume overload (pulmonary edema, severe hypertension)
  • Inability to safely administer fluids due to cardiac dysfunction
  • Severe hyperosmolality (>350 mOsm/kg) requiring rapid but controlled correction

Emergency dialysis allows:

  • Controlled correction of acidosis
  • Precise volume management without fluid overload risk
  • Potassium removal
  • Gradual osmolality correction

Monitoring Intensity

Check every 1-2 hours initially:

  • Glucose (capillary or venous)
  • Electrolytes (Na, K, Cl, HCO3)
  • Venous pH (arterial blood gases unnecessary) 2, 7
  • Calculate effective osmolality: 2[Na] + glucose/18 3

Continuous monitoring:

  • Cardiac telemetry (for hyperkalemia, CAD risk)
  • Oxygen saturation (for pulmonary edema)
  • Fluid balance (strict input/output)

Resolution Criteria - Same Goals, Different Path

DKA resolution: 2, 7, 2

  • Glucose <200 mg/dL
  • Serum bicarbonate ≥18 mEq/L
  • Venous pH >7.3

HHS resolution:

  • Glucose <300 mg/dL
  • Effective osmolality <320 mOsm/kg
  • Mental status normalized

Transition to subcutaneous insulin:

  • Continue IV insulin for 1-2 hours after starting subcutaneous regimen 7
  • In dialysis patients, reduce total daily dose by 20-30% from calculated needs 8
  • Use basal-bolus regimen (not sliding scale alone) 1, 9

Special Considerations for Your Patient's Comorbidities

CVA history:

  • Avoid rapid osmolality shifts (cerebral edema risk, though lower in adults) 2
  • Target osmolality reduction <3 mOsm/kg/h
  • Monitor neurological status closely

CAD s/p PTCA:

  • Minimize volume overload (precipitates acute coronary syndrome)
  • Maintain adequate perfusion pressure
  • Consider cardiology consultation if chest pain or ECG changes
  • Phosphate replacement may be indicated if <1.0 mg/dL to avoid cardiac dysfunction 2, 7

Hypertension:

  • May worsen with volume overload from standard fluid protocols
  • Dialysis provides better volume control than diuretics in this setting 10
  • Continue home antihypertensives unless hypotensive

Common Pitfalls to Avoid

  1. Using standard fluid protocols - will cause pulmonary edema and death
  2. Standard insulin dosing - causes severe, prolonged hypoglycemia
  3. Routine potassium supplementation - causes fatal hyperkalemia
  4. Delaying dialysis consultation - dialysis is often the safest management tool
  5. Treating "by the book" - standard guidelines explicitly warn against this in renal failure 1

The evidence is clear but limited: no randomized trials exist for DKA/HHS management in dialysis patients 5, 6, 11. However, the physiologic principles and case series consistently demonstrate that standard protocols cause harm. When in doubt, use less fluid, less insulin, and involve nephrology early for potential dialysis.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.